ArticleFrontiers in oncology2026
Case Report: Metachronous bilateral primary and secondary angiosarcoma of the breast.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast angiosarcoma (AS) is an extremely rare and aggressive malignancy with no standardized treatment guidelines. We report an exceptional case of metachronous bilateral primary and secondary AS in a single patient, highlighting the diagnostic and therapeutic challenges posed by this disease. Case presentation: A patient underwent surgical dissection for primary AS of the right breast. Seven months later, a primary AS was identified in the left breast. Four months after that, a secondary angiosarcoma also developed within the previously irradiated left chest wall and axilla. Postoperative pathology confirmed angiosarcoma in all resected specimens. Following multidisciplinary team discussion, the patient received simple mastectomy, adjuvant chemotherapy, and radiotherapy. Despite this multimodal approach, contrast-enhanced CT follow-up revealed rapid disease progression with distant metastases to the lungs, liver, spleen, bilateral adnexa, and bones. The patient ultimately died of respiratory failure secondary to severe pulmonary infection and atelectasis 22 months after the initial diagnosis. Conclusion: This extraordinarily rare case of sequential bilateral primary and secondary breast AS underscores the aggressive biological behavior of this malignancy and the limitations of current therapeutic strategies. It highlights the urgent need for identifying specific diagnostic biomarkers and novel therapeutic targets to enable early detection and improve the dismal prognosis associated with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.